Asuragen Launches QuantideX® NGS RNA Lung Cancer Kit (RUO)
Highly Sensitive Targeted RNA Sequencing Panel for the Analysis of Gene Fusions and Expression Markers in Non-Small Cell Lung Cancer
Austin, Texas – November 1, 2016 – Asuragen Inc., a global molecular diagnostics company, announced today the launch of the QuantideX® NGS RNA Lung Cancer Kit1, a next generation sequencing panel that simultaneously interrogates known clinically-relevant gene fusions, 3’/5’ imbalance markers, exon skipping events, and mRNA expression levels in non-small cell lung cancer (NSCLC) samples.
The QuantideX® RNA Lung Cancer Kit is a cGMP manufactured, end-to-end NGS-in-a-Box™ product solution. The kit is part of an integrated workflow that delivers sequencing-ready libraries in approximately half the time of comparable competitor methods and incorporates push-button analytics that standardize results. Asuragen’s proprietary Sample-Aware™ bioinformatics software solution minimizes the subjective results commonly associated with less integrated product offerings currently on market.
“The ability of the QuantideX NGS RNA Lung Cancer Kit to detect both common and rare fusion transcripts and exon splicing events within an integrated wet-bench workflow and companion bioinformatics software, provides a foundation for the reliable detection of oncogenic RNA fusions and aberrant splicing events that respond to current and emerging targeted therapies,” said product evaluation site leader Dr. Léon van Kempen, Chief Operating Officer and Scientific Director, Dubrovsky Molecular Pathology Centre at Jewish General Hospital in Montreal, Canada.
The Asuragen QuantideX® NGS RNA Lung Cancer Kit is optimized for use with low-quality and quantity samples such as FFPE and fine-needle aspirations. The highly sensitive assay detects fusions and splice variants at 5% and 1% cell fractions, respectively.
“With the release of this new RNA-Seq assay, Asuragen is providing the most comprehensive and sensitive research tool for examining >100 clinically-relevant NSCLC gene rearrangements across 11 different fusion partners,” commented Matthew McManus, M.D., Ph.D., President and Chief Executive Officer, Asuragen Inc. “In providing an integrated and comprehensive workflow solution, Asuragen’s NGS assays reduce the barrier-to-entry for laboratories considering targeted NGS oncology assays while also providing new options for laboratories already familiar with NGS technology.”
The development of the QuantideX® RNA Lung Cancer Kit was funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Product Development Research grant.
1For Research Use Only. Not for use in diagnostic procedures.
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery and development to regulatory support to global commercialization, we also provide a tailored approach that efficiently delivers custom and companion diagnostic products for our partners. We believe people deserve better answers. For more information, visit www.asuragen.com.
SVP, Corporate Development and CFO